In this initial clinical trial, 2,000 neural precursor cells grown from iPS cells were injected into the injured area of a patient who was completely paralyzed. These original iPS cell transplants, after being processed by reprogramming technology, have the potential to turn into nerve cells. The patient then underwent a month of immunoblocking therapy to prevent a reaction in Quad.
Participants were previously assessed as having the highest level of impairment (AISA level), which means complete loss of sensory and motor functions below the injury site. The cognitive results after one year showed that two patients did not see significant improvement; one patient recovered to level C and was able to move some limbs but was still unable to achieve stable treatment; most cases recovered to level D (normal level E), at which point they were able to be independent and start walking training.
There are currently 20 million neonatal injury patients worldwide, and traditional treatment methods have limited effects. iPS cell therapy not only rebuilds nerve connections but also promotes repair by converting newborns into neurons and support cells. However, mortality of transplanted cells remains a significant challenge, with many cells dying or regenerating within days.
The next step of the research team's research will focus on determining the types of patients most suitable for treatment, as well as treatment options. This breakthrough progress in optimizing regenerative medicine takes an important step in the field of treating paralysis and brings new hope to patients.